Med Sci Monit 17:677682 Remington R, Bechtel C, Larsen D, Samar A, Doshanjh L, Fishman P, Luo Y, Smyers K, Page R, Morrell C, Shea TB (2015) A phase II Randomized clinical trial of a nutritional formulation for cognition and mood in Alzheimer's disease
Recurring automated marketing texts from Petratide Science
Nausea is the most commonly reported side effect, and antiemetic or prokinetic agents may be recommended for short-term use when it is severe or persistent
Specific data showed that headache relief was 23.6% in the zavegepant group compared to 14.9% in the placebo group, and MBS relief was 39.6% in the zavegepant group compared to 31.1% in the placebo group
Clinical correlates and familial aggregation of age at onset in bipolar disorder